Ptc Therapeutics (PTCT) Accumulated Expenses (2012 - 2026)

Ptc Therapeutics' Accumulated Expenses history runs 13 years deep, the most recent figure standing at $33.8 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 363.29% year-over-year to $33.8 million; the TTM figure through Mar 2026 stood at $33.8 million (up 363.29% YoY), while the FY2025 annual figure was $9.6 million, up 6.94% from the prior year.
• Accumulated Expenses was $33.8 million for Q1 2026 at Ptc Therapeutics, up from $9.6 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $74.1 million in Q4 2023 to a low of $5.1 million in Q3 2025.
• Historically, Accumulated Expenses has averaged $32.4 million across 5 years, with a median of $35.8 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses jumped 6034.0% in 2022, then plunged 88.86% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $40.5 million in 2022, then soared by 82.78% to $74.1 million in 2023, then plunged by 87.92% to $9.0 million in 2024, then gained by 6.94% to $9.6 million in 2025, then jumped by 253.49% to $33.8 million in 2026.
• The last three Accumulated Expenses figures came in at $33.8 million (Q1 2026), $9.6 million (Q4 2025), and $5.1 million (Q3 2025), per Business Quant data.